by Disentangling primer interactions improves SARS-CoV-2 genome sequencing by multiplex tiling PCR
Since December 2019, the coronavirus illness 2019 (COVID-19) brought on by a novel coronavirus SARS-CoV-2 has quickly unfold to nearly each nation on this planet. Quickly after the pandemic was acknowledged by epidemiologists, a bunch of biologists comprising the ARTIC Community, has devised a multiplexed polymerase chain response (PCR) protocol and primer set for focused whole-genome amplification of SARS-CoV-2.
The ARTIC primer set amplifies 98 amplicons, that are separated solely in two PCRs, throughout a virtually complete viral genome. The unique primer set and protocol confirmed a reasonably small amplification bias when scientific samples with comparatively excessive viral hundreds had been used.
Nonetheless, as pattern’s viral load turn into low, speedy lower in abundances of a number of amplicons had been seen. On this report, we’ll present that dimer formations between some primers are the key explanation for protection bias within the multiplex PCR. Based mostly on this, we suggest 12 different primers in whole within the ARTIC primer set that had been predicted to be concerned in 14 primer interactions.
The ensuing primer set, model N1 (NIID-1), displays improved general protection in comparison with the ARTIC Community’s unique (V1) and modified (V3) primer set.
RLIM Polyclonal Antibody |
|||
| 29447-50ul | SAB | 50ul | EUR 187 |
RLIM siRNA |
|||
| 20-abx931585 | Abbexa |
|
|
RLIM siRNA |
|||
| 20-abx931586 | Abbexa |
|
|
RLIM Polyclonal Conjugated Antibody |
|||
| C29447 | SAB | 100ul | EUR 397 |
RLIM Rabbit pAb |
|||
| A15837-100ul | Abclonal | 100 ul | EUR 308 |
RLIM Rabbit pAb |
|||
| A15837-200ul | Abclonal | 200 ul | EUR 459 |
RLIM Rabbit pAb |
|||
| A15837-20ul | Abclonal | 20 ul | EUR 183 |
RLIM Rabbit pAb |
|||
| A15837-50ul | Abclonal | 50 ul | EUR 223 |
RLIM Blocking Peptide |
|||
| DF12723-BP | Affbiotech | 1mg | EUR 195 |
Mouse E3 ubiquitin- protein ligase RLIM, Rlim ELISA KIT |
|||
| ELI-52811m | Lifescience Market | 96 Tests | EUR 865 |
Human E3 ubiquitin- protein ligase RLIM, RLIM ELISA KIT |
|||
| ELI-40904h | Lifescience Market | 96 Tests | EUR 824 |
Polyclonal Goat anti-GST α-form |
|||
| GST-ANTI-1 | Detroit R&D | 50 uL | EUR 280 |
Polyclonal Goat anti-GST μ-form |
|||
| GST-ANTI-2 | Detroit R&D | 50 uL | EUR 280 |
Polyclonal Goat anti-GST p-form |
|||
| GST-ANTI-3 | Detroit R&D | 50 uL | EUR 280 |
Mouse RLIM shRNA Plasmid |
|||
| 20-abx972467 | Abbexa |
|
|
Human RLIM shRNA Plasmid |
|||
| 20-abx959551 | Abbexa |
|
|
RLIM ELISA KIT|Human |
|||
| EF002487 | Lifescience Market | 96 Tests | EUR 689 |
RLIM Recombinant Protein (Human) |
|||
| RP026497 | ABM | 100 ug | Ask for price |
RLIM Recombinant Protein (Mouse) |
|||
| RP168323 | ABM | 100 ug | Ask for price |
RLIM Recombinant Protein (Rat) |
|||
| RP226193 | ABM | 100 ug | Ask for price |
Rlim ORF Vector (Rat) (pORF) |
|||
| ORF075399 | ABM | 1.0 ug DNA | EUR 506 |
RLIM ORF Vector (Human) (pORF) |
|||
| ORF008833 | ABM | 1.0 ug DNA | EUR 95 |
Rlim ORF Vector (Mouse) (pORF) |
|||
| ORF056109 | ABM | 1.0 ug DNA | EUR 506 |
Ring Finger Protein, Lim Domain Interacting (RLIM) Antibody |
|||
| 20-abx115301 | Abbexa |
|
|
Ring Finger Protein, LIM Domain Interacting (RLIM) Antibody |
|||
| abx237320-100ug | Abbexa | 100 ug | EUR 509 |
RLIM sgRNA CRISPR Lentivector set (Human) |
|||
| K1827101 | ABM | 3 x 1.0 ug | EUR 339 |
Rlim sgRNA CRISPR Lentivector set (Rat) |
|||
| K6457601 | ABM | 3 x 1.0 ug | EUR 339 |
Rlim sgRNA CRISPR Lentivector set (Mouse) |
|||
| K5023801 | ABM | 3 x 1.0 ug | EUR 339 |
RLIM sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K1827102 | ABM | 1.0 ug DNA | EUR 154 |
RLIM sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K1827103 | ABM | 1.0 ug DNA | EUR 154 |
RLIM sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K1827104 | ABM | 1.0 ug DNA | EUR 154 |
Rlim sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K6457602 | ABM | 1.0 ug DNA | EUR 154 |
Rlim sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K6457603 | ABM | 1.0 ug DNA | EUR 154 |
Rlim sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K6457604 | ABM | 1.0 ug DNA | EUR 154 |
Rlim sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K5023802 | ABM | 1.0 ug DNA | EUR 154 |
Rlim sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K5023803 | ABM | 1.0 ug DNA | EUR 154 |
Rlim sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K5023804 | ABM | 1.0 ug DNA | EUR 154 |
RLIM 3'UTR GFP Stable Cell Line |
|||
| TU069947 | ABM | 1.0 ml | EUR 4617 |
RLIM Protein Vector (Rat) (pPB-C-His) |
|||
| PV301594 | ABM | 500 ng | EUR 603 |
RLIM Protein Vector (Rat) (pPB-N-His) |
|||
| PV301595 | ABM | 500 ng | EUR 603 |
RLIM Protein Vector (Rat) (pPM-C-HA) |
|||
| PV301596 | ABM | 500 ng | EUR 603 |
RLIM Protein Vector (Rat) (pPM-C-His) |
|||
| PV301597 | ABM | 500 ng | EUR 603 |
RLIM Protein Vector (Human) (pPB-C-His) |
|||
| PV035329 | ABM | 500 ng | EUR 329 |
RLIM Protein Vector (Human) (pPB-N-His) |
|||
| PV035330 | ABM | 500 ng | EUR 329 |
RLIM Protein Vector (Human) (pPM-C-HA) |
|||
| PV035331 | ABM | 500 ng | EUR 329 |
RLIM Protein Vector (Human) (pPM-C-His) |
|||
| PV035332 | ABM | 500 ng | EUR 329 |
RLIM Protein Vector (Mouse) (pPB-C-His) |
|||
| PV224434 | ABM | 500 ng | EUR 603 |
RLIM Protein Vector (Mouse) (pPB-N-His) |
|||
| PV224435 | ABM | 500 ng | EUR 603 |
RLIM Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV224436 | ABM | 500 ng | EUR 603 |
RLIM Protein Vector (Mouse) (pPM-C-His) |
|||
| PV224437 | ABM | 500 ng | EUR 603 |
Rlim 3'UTR Luciferase Stable Cell Line |
|||
| TU219467 | ABM | 1.0 ml | Ask for price |
RLIM 3'UTR Luciferase Stable Cell Line |
|||
| TU019947 | ABM | 1.0 ml | EUR 4617 |
Rlim 3'UTR GFP Stable Cell Line |
|||
| TU269467 | ABM | 1.0 ml | Ask for price |
Rlim 3'UTR Luciferase Stable Cell Line |
|||
| TU117914 | ABM | 1.0 ml | Ask for price |
Rlim 3'UTR GFP Stable Cell Line |
|||
| TU167914 | ABM | 1.0 ml | Ask for price |
Human Ring Finger Protein, LIM Domain Interacting (RLIM) ELISA Kit |
|||
| abx382827-96tests | Abbexa | 96 tests | EUR 911 |
RLIM sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K1827105 | ABM | 3 x 1.0 ug | EUR 376 |
Rlim sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
| K6457605 | ABM | 3 x 1.0 ug | EUR 376 |
Rlim sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
| K5023805 | ABM | 3 x 1.0 ug | EUR 376 |
RLIM sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K1827106 | ABM | 1.0 ug DNA | EUR 167 |
RLIM sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K1827107 | ABM | 1.0 ug DNA | EUR 167 |
RLIM sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K1827108 | ABM | 1.0 ug DNA | EUR 167 |
Rlim sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
| K6457606 | ABM | 1.0 ug DNA | EUR 167 |
Rlim sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|||
| K6457607 | ABM | 1.0 ug DNA | EUR 167 |
Rlim sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|||
| K6457608 | ABM | 1.0 ug DNA | EUR 167 |
Rlim sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
|||
| K5023806 | ABM | 1.0 ug DNA | EUR 167 |
Rlim sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
|||
| K5023807 | ABM | 1.0 ug DNA | EUR 167 |
Rlim sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
|||
| K5023808 | ABM | 1.0 ug DNA | EUR 167 |
Anti-Anti-SEPT2 Antibody antibody |
|||
| STJ25475 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-SEPT5 Antibody antibody |
|||
| STJ25477 | St John's Laboratory | 100 µl | EUR 277 |
|
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
|||
Anti-Anti-SEPT8 Antibody antibody |
|||
| STJ25479 | St John's Laboratory | 100 µl | EUR 277 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Anti-SEPT2 Antibody antibody |
|||
| STJ28365 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-SEPT7 Antibody antibody |
|||
| STJ28963 | St John's Laboratory | 100 µl | EUR 277 |
|
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
|||
Anti-Anti-SEPT8 Antibody antibody |
|||
| STJ117206 | St John's Laboratory | 100 µl | EUR 277 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Anti-SEPT12 Antibody antibody |
|||
| STJ117759 | St John's Laboratory | 100 µl | EUR 277 |
|
Description: This gene encodes a guanine-nucleotide binding protein and member of the septin family of cytoskeletal GTPases. Septins play important roles in cytokinesis, exocytosis, embryonic development, and membrane dynamics. Multiple transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Anti-MARCH6 Antibody antibody |
|||
| STJ118549 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-MARCH6 Antibody antibody |
|||
| STJ118550 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-MARCH7 Antibody antibody |
|||
| STJ118752 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-SEPT3 Antibody antibody |
|||
| STJ118990 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-SEPT1 antibody antibody |
|||
| STJ119580 | St John's Laboratory | 100 µl | EUR 277 |
|
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis and the maintenance of cellular morphology. This gene encodes a protein that can form homo- and heterooligomeric filaments, and may contribute to the formation of neurofibrillary tangles in Alzheimer's disease. Alternatively spliced transcript variants have been found but the full-length nature of these variants has not been determined. [provided by RefSeq, Dec 2012] |
|||
Anti-Anti-SEPT7 Antibody antibody |
|||
| STJ116214 | St John's Laboratory | 100 µl | EUR 277 |
|
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
|||
Anti-Anti-SEPT6 antibody antibody |
|||
| STJ11100949 | St John's Laboratory | 100 µl | EUR 277 |
|
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined. |
|||
Anti-Anti-SEPT9 Antibody antibody |
|||
| STJ111369 | St John's Laboratory | 100 µl | EUR 277 |
|
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described. |
|||
Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ111530 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-SEPT4 Antibody antibody |
|||
| STJ112276 | St John's Laboratory | 100 µl | EUR 277 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer. |
|||
Anti-Anti-MARCH9 Antibody antibody |
|||
| STJ112609 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ113941 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ114081 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-SEPT5 Antibody antibody |
|||
| STJ114819 | St John's Laboratory | 100 µl | EUR 277 |
|
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
|||
Anti-Anti-MARCH8 Antibody antibody |
|||
| STJ114828 | St John's Laboratory | 100 µl | EUR 277 |
Anti-Anti-DDB1 Antibody |
|||
| A00333 | BosterBio | 100uL | EUR 455 |
|
Description: Rabbit Polyclonal DDB1 Antibody. Validated in IP and tested in Human, Mouse. |
|||
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit |
|||
| AEA465Hu-10x96wellstestplate | Cloud-Clone | 10x96-wells test plate | EUR 5647.8 |
|
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids. |
|||
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit |
|||
| AEA465Hu-1x48wellstestplate | Cloud-Clone | 1x48-wells test plate | EUR 552.76 |
|
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids. |
|||
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit |
|||
| AEA465Hu-1x96wellstestplate | Cloud-Clone | 1x96-wells test plate | EUR 746.8 |
|
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids. |
|||
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit |
|||
| AEA465Hu-5x96wellstestplate | Cloud-Clone | 5x96-wells test plate | EUR 3060.6 |
|
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids. |
|||
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit |
|||
| 4-AEA465Hu | Cloud-Clone |
|
|
|
Description: Enzyme-linked immunosorbent assay based on the Competitive Inhibition method for detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in samples from serum, plasma and other biological fluids with no significant corss-reactivity with analogues from other species. |
|||
ELISA kit for Human Anti-AsAb (Anti-Anti-Sperm Antibody Antibody) |
|||
| ELK8071 | ELK Biotech | 1 plate of 96 wells | EUR 432 |
|
Description: A competitive Inhibition ELISA kit for detection of Anti-Anti-Sperm Antibody Antibody from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids. |
|||
Anti-FGF1 Antibody |
|||
| RP1005 | BosterBio | 100ug/vial | EUR 334 |
Anti-FGF2 Antibody |
|||
| RP1006 | BosterBio | 100ug/vial | EUR 334 |
Anti-IL3 Antibody |
|||
| RP1008 | BosterBio | 100ug/vial | EUR 334 |
Anti-IL4 Antibody |
|||
| RP1009 | BosterBio | 100ug/vial | EUR 334 |
Anti-DDT Antibody |
|||
| RP1011 | BosterBio | 100ug/vial | EUR 334 |
Anti-IL6 Antibody |
|||
| RP1012 | BosterBio | 100ug/vial | EUR 294 |
Anti-IL7 Antibody |
|||
| RP1013 | BosterBio | 100ug/vial | EUR 294 |
Anti-IL10 Antibody |
|||
| RP1014 | BosterBio | 100ug/vial | EUR 334 |
Anti-IL10 Antibody |
|||
| RP1015 | BosterBio | 100ug/vial | EUR 294 |
Anti-IL10 Antibody |
|||
| RP1016 | BosterBio | 100ug/vial | EUR 334 |
Anti-IL18 Antibody |
|||
| RP1017 | BosterBio | 100ug/vial | EUR 334 |
Anti-CEACAM5 Antibody |
|||
| RP1018 | BosterBio | 100ug/vial | EUR 334 |
Anti-MIF Antibody |
|||
| RP1020 | BosterBio | 100ug/vial | EUR 294 |
Anti-NGF Antibody |
|||
| RP1025 | BosterBio | 100ug/vial | EUR 294 |
Anti-FOXP3 Antibody |
|||
| RP1032 | BosterBio | 100ug/vial | EUR 334 |
Anti-MUC2 Antibody |
|||
| RP1038 | BosterBio | 100ug/vial | EUR 334 |
Anti-ATM Antibody |
|||
| RP1040 | BosterBio | 100ug/vial | EUR 294 |
Anti-CBS Antibody |
|||
| RP1041 | BosterBio | 100ug/vial | EUR 334 |
Anti-IL3 Antibody |
|||
| RP1046 | BosterBio | 100ug/vial | EUR 294 |
Anti-IL13 Antibody |
|||
| RP1047 | BosterBio | 100ug/vial | EUR 294 |
Anti-IL13 Antibody |
|||
| RP1048 | BosterBio | 100ug/vial | EUR 294 |
Anti-MBD2 Antibody |
|||
| RP1049 | BosterBio | 100ug/vial | EUR 294 |
Anti-FRZB Antibody |
|||
| RP1061 | BosterBio | 100ug/vial | EUR 294 |
Anti-HGF Antibody |
|||
| RP1062 | BosterBio | 100ug/vial | EUR 294 |
Anti-PLD1 Antibody |
|||
| RP1063 | BosterBio | 100ug/vial | EUR 294 |
Anti-MAFA Antibody |
|||
| RP1066 | BosterBio | 100ug/vial | EUR 294 |
Anti-SFRP4 Antibody |
|||
| RP1067 | BosterBio | 100ug/vial | EUR 294 |
Anti-AGFG1 Antibody |
|||
| RP1071 | BosterBio | 100ug/vial | EUR 294 |
Anti-SP1 Antibody |
|||
| RP1072 | BosterBio | 100ug/vial | EUR 294 |
Anti-TLR8 Antibody |
|||
| RP1073 | BosterBio | 100ug/vial | EUR 294 |
Anti-CD59 Antibody |
|||
| RP1076 | BosterBio | 100ug/vial | EUR 334 |
Anti-TSG101 Antibody |
|||
| RP1078 | BosterBio | 100ug/vial | EUR 294 |
Anti-CYP7A1 Antibody |
|||
| RP1079 | BosterBio | 100ug/vial | EUR 294 |
Anti-DMRT1 Antibody |
|||
| RP1083 | BosterBio | 100ug/vial | EUR 334 |
Anti-FABP4 Antibody |
|||
| RP1085 | BosterBio | 100ug/vial | EUR 334 |
Anti-PTOV1 Antibody |
|||
| RP1087 | BosterBio | 100ug/vial | EUR 294 |
Anti-Wnt7a Antibody |
|||
| RP1088 | BosterBio | 100ug/vial | EUR 334 |
Anti-MMP12 Antibody |
|||
| RP1089 | BosterBio | 100ug/vial | EUR 294 |
Anti-HSD11B2 Antibody |
|||
| RP1094 | BosterBio | 100ug/vial | EUR 294 |
Anti-CD33 Antibody |
|||
| RP1105 | BosterBio | 100ug/vial | EUR 334 |
Anti-VIP Antibody |
|||
| RP1108 | BosterBio | 100ug/vial | EUR 334 |
Anti-SHANK3 Antibody |
|||
| RP1109 | BosterBio | 100ug/vial | EUR 294 |
Anti-ADH5 Antibody |
|||
| RP1111 | BosterBio | 100ug/vial | EUR 334 |
Anti-Calbindin Antibody |
|||
| M03047-2 | BosterBio | 100ul | EUR 397 |
|
Description: Chicken Polyclonal Calbindin Antibody. Validated in IF, IHC, WB and tested in Bovine, Human, Mouse, Rat. |
|||
Anti-Fibrillarin Antibody |
|||
| M03178-4 | BosterBio | 100ul | EUR 397 |
|
Description: Rabbit Polyclonal Fibrillarin Antibody. Validated in IP, IHC, WB and tested in Human, Mouse, Rat. |
|||
Anti-Fibrillarin Antibody |
|||
| M03178-5 | BosterBio | 100ul | EUR 397 |
|
Description: Chicken Polyclonal Fibrillarin Antibody. Validated in IF, IHC, WB and tested in Bovine, Chicken, Equine, Human, Mouse, Pig, Rat. |
|||
Acyclovir-induced neurotoxicity with a constructive cerebrospinal fluid varicella zoster PCR outcome making a administration dilemma: a case report
Background: Varicella zoster virus central nervous system infections can current as aseptic meningitis, encephalitis, myelitis, and vasculopathy. Analysis is predicated on identification of varicella zoster virus deoxyribonucleic acid (DNA) within the cerebrospinal fluid by polymerase chain response. Remedy for these infections is acyclovir or valacyclovir.
Nonetheless, acyclovir can have neurotoxic results that may mimic the presentation of varicella zoster virus central nervous system illness. We current a uncommon presentation of a affected person who had acyclovir-induced neurotoxicity who additionally had a false-positive cerebrospinal fluid varicella zoster virus polymerase chain response outcome, making a administration dilemma.
We evaluate the scientific traits of acyclovir-induced neurotoxicity. As well as, we current the diagnostic traits of the cerebrospinal fluid viral polymerase chain response and different strategies to diagnose central nervous system varicella zoster virus illness.
Case presentation: A 68-year-old Hispanic man with end-stage renal illness was recognized with cutaneous zoster at an outdoor facility and was began on acyclovir four days previous to admission. His household famous worsening confusion, agitation, speech issue, and hallucinations, main them to carry him to the emergency division.
His cerebrospinal fluid varicella zoster virus polymerase
chain response outcome was constructive, indicating the presence of varicella zoster virus deoxyribonucleic acid within the cerebrospinal fluid; nonetheless, he didn’t have cerebrospinal fluid pleocytosis typical of varicella zoster virus meningoencephalitis.
Pharmacy information from the surface hospital revealed supratherapeutic acyclovir dosing. This led to a diagnostic dilemma over whether or not this affected person had varicella zoster virus encephalitis or acyclovir-induced neurotoxicity. Acyclovir was discontinued, and the affected person underwent two periods of hemodialysis to take away acyclovir, which led to a full neurologic restoration.
Conclusions: Varicella zoster virus encephalitis and acyclovir-induced neurotoxicity can have comparable displays. Varicella zoster virus deoxyribonucleic acid will be current within the cerebrospinal fluid throughout lively cutaneous zoster within the absence of central nervous system illness. If concern for central nervous system varicella zoster virus illness stays excessive, further testing with cerebrospinal fluid serology will be carried out.
In contrast with central nervous system varicella zoster virus illness, acyclovir-induced neurotoxicity has a extra predictable scientific decision as soon as drug remedy is discontinued or the affected person undergoes hemodialysis, which might support in making the prognosis. Clinicians ought to pay attention to this uncommon and harmful complication of acyclovir.
As well as, clinicians ought to have an understanding of the diagnostic limitations of cerebrospinal fluid viral polymerase chain response and have different approaches out there to diagnose central nervous system varicella zoster virus illness when it’s suspected.
Canine C-Peptide ELISA Kit |
|||
| DLR-C-Peptide-c-96T | DL Develop | 96T | EUR 688 |
|
Description: A competitive inhibition quantitative ELISA assay kit for detection of Canine C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Human C-Peptide ELISA Kit |
|||
| DLR-C-Peptide-Hu-48T | DL Develop | 48T | EUR 398 |
|
Description: A competitive inhibition quantitative ELISA assay kit for detection of Human C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Human C-Peptide ELISA Kit |
|||
| DLR-C-Peptide-Hu-96T | DL Develop | 96T | EUR 511 |
|
Description: A competitive inhibition quantitative ELISA assay kit for detection of Human C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Mouse C-Peptide ELISA Kit |
|||
| DLR-C-Peptide-Mu-48T | DL Develop | 48T | EUR 450 |
|
Description: A competitive inhibition quantitative ELISA assay kit for detection of Mouse C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Mouse C-Peptide ELISA Kit |
|||
| DLR-C-Peptide-Mu-96T | DL Develop | 96T | EUR 582 |
|
Description: A competitive inhibition quantitative ELISA assay kit for detection of Mouse C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Rat C-Peptide ELISA Kit |
|||
| DLR-C-Peptide-Ra-48T | DL Develop | 48T | EUR 467 |
|
Description: A competitive inhibition quantitative ELISA assay kit for detection of Rat C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Rat C-Peptide ELISA Kit |
|||
| DLR-C-Peptide-Ra-96T | DL Develop | 96T | EUR 605 |
|
Description: A competitive inhibition quantitative ELISA assay kit for detection of Rat C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Canine C-Peptide ELISA Kit |
|||
| RDR-C-Peptide-c-48Tests | Reddot Biotech | 48 Tests | EUR 557 |
Canine C-Peptide ELISA Kit |
|||
| RDR-C-Peptide-c-96Tests | Reddot Biotech | 96 Tests | EUR 774 |
Human C-Peptide ELISA Kit |
|||
| RDR-C-Peptide-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 404 |
Human C-Peptide ELISA Kit |
|||
| RDR-C-Peptide-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 556 |
Mouse C-Peptide ELISA Kit |
|||
| RDR-C-Peptide-Mu-48Tests | Reddot Biotech | 48 Tests | EUR 465 |
Mouse C-Peptide ELISA Kit |
|||
| RDR-C-Peptide-Mu-96Tests | Reddot Biotech | 96 Tests | EUR 643 |
Rat C-Peptide ELISA Kit |
|||
| RDR-C-Peptide-Ra-48Tests | Reddot Biotech | 48 Tests | EUR 486 |
Rat C-Peptide ELISA Kit |
|||
| RDR-C-Peptide-Ra-96Tests | Reddot Biotech | 96 Tests | EUR 672 |
CD39 Blocking Peptide |
|||
| P10103 | Neuromics | 20 ug Blocking Peptide | EUR 146 |
P2X3 Blocking Peptide |
|||
| P10108 | Neuromics | 100 ug Blocking Peptide | EUR 146 |
CXCL1 Blocking Peptide |
|||
| 20-abx061039 | Abbexa |
|
|
p21 Blocking Peptide |
|||
| 20-abx061043 | Abbexa |
|
|
Dyskerin Blocking Peptide |
|||
| 20-abx061050 | Abbexa |
|
|
ZNF265 Blocking Peptide |
|||
| 20-abx061051 | Abbexa |
|
|
CDK11B Blocking Peptide |
|||
| 20-abx061053 | Abbexa |
|
|
HMGB2 Blocking Peptide |
|||
| 20-abx061056 | Abbexa |
|
|
ZFP36L2 Blocking Peptide |
|||
| 20-abx061059 | Abbexa |
|
|
CBP20 Blocking Peptide |
|||
| 20-abx061060 | Abbexa |
|
|
FOXE3 Blocking Peptide |
|||
| 20-abx061063 | Abbexa |
|
|
CBFB Blocking Peptide |
|||
| 20-abx061064 | Abbexa |
|
|
MAPKAPK3 Blocking Peptide |
|||
| 20-abx061065 | Abbexa |
|
|
MOB3C Blocking Peptide |
|||
| 20-abx061067 | Abbexa |
|
|
DPF2 Blocking Peptide |
|||
| 20-abx061068 | Abbexa |
|
|
TAF15 Blocking Peptide |
|||
| 20-abx061069 | Abbexa |
|
|
FAM84B Blocking Peptide |
|||
| 20-abx061070 | Abbexa |
|
|
GTF2IRD1 Blocking Peptide |
|||
| 20-abx061071 | Abbexa |
|
|
COL19A1 Blocking Peptide |
|||
| 20-abx061072 | Abbexa |
|
|
CYP2W1 Blocking Peptide |
|||
| 20-abx061073 | Abbexa |
|
|
RAD21 Blocking Peptide |
|||
| 20-abx061075 | Abbexa |
|
|
PSMC3 Blocking Peptide |
|||
| 20-abx061076 | Abbexa |
|
|
PSMD11 Blocking Peptide |
|||
| 20-abx061077 | Abbexa |
|
|
MRPS9 Blocking Peptide |
|||
| 20-abx061078 | Abbexa |
|
|
MRPL41 Blocking Peptide |
|||
| 20-abx061079 | Abbexa |
|
|
MRPL48 Blocking Peptide |
|||
| 20-abx061080 | Abbexa |
|
|
RPS12 Blocking Peptide |
|||
| 20-abx061081 | Abbexa |
|
|
RPS13 Blocking Peptide |
|||
| 20-abx061082 | Abbexa |
|
|
ACSS1 Blocking Peptide |
|||
| 20-abx061084 | Abbexa |
|
|
AKR1C2 Blocking Peptide |
|||
| 20-abx061085 | Abbexa |
|
|
ACER3 Blocking Peptide |
|||
| 20-abx061086 | Abbexa |
|
|
ATP5I Blocking Peptide |
|||
| 20-abx061087 | Abbexa |
|
|
ATP5C1 Blocking Peptide |
|||
| 20-abx061088 | Abbexa |
|
|
CNTROB Blocking Peptide |
|||
| 20-abx061089 | Abbexa |
|
|
CEP78 Blocking Peptide |
|||
| 20-abx061090 | Abbexa |
|
|
DMGDH Blocking Peptide |
|||
| 20-abx061093 | Abbexa |
|
|
EIF3D Blocking Peptide |
|||
| 20-abx061095 | Abbexa |
|
|
FUBP3 Blocking Peptide |
|||
| 20-abx061096 | Abbexa |
|
|
GHITM Blocking Peptide |
|||
| 20-abx061097 | Abbexa |
|
|
SAR1B Blocking Peptide |
|||
| 20-abx061098 | Abbexa |
|
|
NXPH3 Blocking Peptide |
|||
| 20-abx061101 | Abbexa |
|
|
PP15 Blocking Peptide |
|||
| 20-abx061102 | Abbexa |
|
|
LONP2 Blocking Peptide |
|||
| 20-abx061104 | Abbexa |
|
|
PEX10 Blocking Peptide |
|||
| 20-abx061105 | Abbexa |
|
|
PABPC5 Blocking Peptide |
|||
| 20-abx061106 | Abbexa |
|
|
PRPF39 Blocking Peptide |
|||
| 20-abx061107 | Abbexa |
|
|
PPM1K Blocking Peptide |
|||
| 20-abx061108 | Abbexa |
|
|
RSAD1 Blocking Peptide |
|||
| 20-abx061109 | Abbexa |
|
|
Renin Blocking Peptide |
|||
| 20-abx061110 | Abbexa |
|
|
SH2D2A Blocking Peptide |
|||
| 20-abx061113 | Abbexa |
|
|
SCN4B Blocking Peptide |
|||
| 20-abx061114 | Abbexa |
|
|
SFRS15 Blocking Peptide |
|||
| 20-abx061115 | Abbexa |
|
|
TCEAL1 Blocking Peptide |
|||
| 20-abx061116 | Abbexa |
|
|
TMBIM4 Blocking Peptide |
|||
| 20-abx061117 | Abbexa |
|
|
WIPF1 Blocking Peptide |
|||
| 20-abx061118 | Abbexa |
|
|
ZFYVE19 Blocking Peptide |
|||
| 20-abx061119 | Abbexa |
|
|
ZNT1 Blocking Peptide |
|||
| 20-abx061120 | Abbexa |
|
|
BNIP3 Blocking Peptide |
|||
| 20-abx061122 | Abbexa |
|
|
SHIP2 Blocking Peptide |
|||
| 20-abx061126 | Abbexa |
|
|
CD248 Blocking Peptide |
|||
| 20-abx061132 | Abbexa |
|
|
CD225 Blocking Peptide |
|||
| 20-abx061133 | Abbexa |
|
|
CD276 Blocking Peptide |
|||
| 20-abx061134 | Abbexa |
|
|
CD300d Blocking Peptide |
|||
| 20-abx061135 | Abbexa |
|
|
GPR10 Blocking Peptide |
|||
| 20-abx061136 | Abbexa |
|
|
GPCR135 Blocking Peptide |
|||
| 20-abx061137 | Abbexa |
|
|
STAT5 Blocking Peptide |
|||
| 20-abx061148 | Abbexa |
|
|
TGFBR2 Blocking Peptide |
|||
| 20-abx061149 | Abbexa |
|
|
ABL1 Blocking Peptide |
|||
| 20-abx061151 | Abbexa |
|
|
SPHK2 Blocking Peptide |
|||
| 20-abx061153 | Abbexa |
|
|
RPS6KC1 Blocking Peptide |
|||
| 20-abx061156 | Abbexa |
|
|
MMTAG2 Blocking Peptide |
|||
| 20-abx061157 | Abbexa |
|
|
MRG15 Blocking Peptide |
|||
| 20-abx061158 | Abbexa |
|
|
CADM1 Blocking Peptide |
|||
| 20-abx061159 | Abbexa |
|
|
APPBP2 Blocking Peptide |
|||
| 20-abx061160 | Abbexa |
|
|
CEP135 Blocking Peptide |
|||
| 20-abx061162 | Abbexa |
|
|
EIF3J Blocking Peptide |
|||
| 20-abx061163 | Abbexa |
|
|
MRPS22 Blocking Peptide |
|||
| 20-abx061164 | Abbexa |
|
|
RIMS4 Blocking Peptide |
|||
| 20-abx061167 | Abbexa |
|
|
RHOBTB3 Blocking Peptide |
|||
| 20-abx061168 | Abbexa |
|
|
OUTB1 Blocking Peptide |
|||
| 20-abx061170 | Abbexa |
|
|
NRBP1 Blocking Peptide |
|||
| 20-abx061171 | Abbexa |
|
|
GPR40 Blocking Peptide |
|||
| 20-abx061175 | Abbexa |
|
|
COX10 Blocking Peptide |
|||
| 20-abx061180 | Abbexa |
|
|
RAB34 Blocking Peptide |
|||
| 20-abx061185 | Abbexa |
|
|
RASD2 Blocking Peptide |
|||
| 20-abx061189 | Abbexa |
|
|
ALT2 Blocking Peptide |
|||
| 20-abx061190 | Abbexa |
|
|
DZIP3 Blocking Peptide |
|||
| 20-abx061191 | Abbexa |
|
|
CaMK4 Blocking Peptide |
|||
| 20-abx061202 | Abbexa |
|
|
Dematin Blocking Peptide |
|||
| 20-abx061203 | Abbexa |
|
|
TBX10 Blocking Peptide |
|||
| 20-abx061209 | Abbexa |
|
|
TAF5L Blocking Peptide |
|||
| 20-abx061210 | Abbexa |
|
|
PSKH1 Blocking Peptide |
|||
| 20-abx061211 | Abbexa |
|
|
ZNF24 Blocking Peptide |
|||
| 20-abx061212 | Abbexa |
|
|
EPHA1 Blocking Peptide |
|||
| 20-abx061213 | Abbexa |
|
|
GTF2H1 Blocking Peptide |
|||
| 20-abx061214 | Abbexa |
|
|
Recoverin Blocking Peptide |
|||
| 20-abx061215 | Abbexa |
|
|
BUD31 Blocking Peptide |
|||
| 20-abx061216 | Abbexa |
|
|
MKK4 Blocking Peptide |
|||
| 20-abx061217 | Abbexa |
|
|
